ts pharmacokinetic data (low oral bioavailability, large volume of distribution, moderately elevated molecular weight and high plasma protein binding) explains the negligible or zero passage into milk observed (Grover 2015, Nordeng 2014, Watanabe 2011, Lutz 2010, Schlotterbeck 2007). No problems were observed in infants whose mothers were taking it (Nordeng 2014, Tarikh 2014, Lutz 2010). The plasma levels of these infants were undetectable or very low (Watanabe 2011). Its relationship with prolactin is controversial because it lowers prolactin levels and has been used to treat prolactinomas and hyperprolactinemia induced by the use of other antipsychotics (Bakker 2016, Ranjbar 2015, Raghuthaman 2015, Safer 2013, Byerly 2009, Lorenz 2007, Goodnick 2002), but cases of decreased milk production have been reported (Frew 2015, Mendhekar 2006) and hyperprolactinemia triggered by aripiprazole has been reported (Sogawa 2016, Prost 2016, Saraf 2014, Mendhekar 2005, Ruffatti 2005). Due to its slow elimination, it may be worthwhile using other compatible antipsychotics with a shorter half-life, especially during the neonatal period and in case of prematurity (Uguz 2016). Monitor for possible drowsiness in the infant (Hale 2017 p.74).